Using Prokinetic Agents in Chronic Intestinal Pseudo-Obstruction (CIPO) Tufts Medicine Yushan Wang MD¹, Saleh Alghsoon MBBS², Suma Gondi MD¹, John Roberts³, Raffi Karagozian MD² **Tufts Medical Center**

¹Department of Internal Medicine at Tufts Medical Center, ²Department of Gastroenterology at Tufts Medical Center, ³Tufts School of Medicine

Introduction

Chronic intestinal pseudo-obstruction (CIPO) is a rare disease.¹ Dilatation may involve the colon or small bowel and is usually due to an underlying neuropathic disorder.² Clinical manifestations of CIPO include abdominal distention, bloating, and pain, which can be acute, chronic, or recurrent.³

Abdominal CT on admission





	Ogilvie's Syndrome ^{4,5,6}	
Prevalence	100 per 100,000*	0.80-1.00 per 1
Course	Acute	Chronic
Anatomic involvement	Colonic dilatation, usually cecum, right colon	Colonic or sma
Presentation	 Abdominal distention Cramping pain Nausea/vomiting 	 Abdominal d Abdominal p Bloating
Patho- physiology	 Multifactorial Autonomic dysfunction strongly implicated 	 Neuropathic Myopathic di Malfunction di Cajal
	 Fluid resuscitation, correction of electrolyte abnormalities, avoidance of opioids/ anticholinergics Ambulation, bowel rest Decompression with NG or rectal tubes Pharmacologic treatment (neostigmine) Operative intervention if colonic perforation or ischemia 	 Dietary modi underlying d Prokinetics, s for symptom Pyridostigmin of CIPO

CIPO

100,000

Il bowel dilatation

listention

disorder isorder of interstitial cells of

ification, treatment of disease

such as Prucalopride, natic relief (Grade 2C) ne in chronic phase

Case Description

62-year-old male presenting with three weeks of worsening abdominal pain and distention. He was initially managed conservatively with bowel rest, rectal tube, and avoidance of opioids. However, serial abdominal X-rays showed no improvement in dilation. He was started on pyridostigmine with significant improvement in dilation and had normal bowel movements prior to discharge.

Past Hospitalizations: He had two recent hospitalizations for similar symptoms thought to be due to non-obstructive ileus. At that time, colonoscopy showed significant colonic dilation with no masses or strictures. He was endoscopically decompressed and started on methylnaltrexone with relative improvement during a prior hospitalization.

use disorder, and L5-S1 fusion on chronic opioids

<u>Home Medications</u>: Oxycodone, methylnaltrexone, polyethylene glycol, bisacodyl

former smoker, current EtOH use

Physical Exam: Massively distended abdomen with minimal tenderness

Pre-pyridostigmine



- Past Medical History: Colon cancer with sigmoid resection/colostomy reversal, alcohol
- <u>Family/Social History</u>: Father (colon cancer), mother (ulcerative colitis s/p colectomy);

Post-pyridostigmine

Discussion

This patient had recurrent CIPO with multiple admissions without complete resolution of previously suspected non-obstructive ileus despite conservative management and methylnaltrexone. Imaging was consistent with severe colonic dilation. As the patient had no improvement with conservative management, he was started on a trial of pyridostigmine after which he had significant improvement of bowel dilation on X-ray with normal bowel movements, illustrating the role of prokinetics in treating suspected CIPO. Knowledge of CIPO is important to prevent delays in diagnosis. Diagnosis of CIPO should be suspected in patients with these symptoms for at least 3 months in the absence of a mechanical cause.¹ Diagnosis requires exclusion of mechanical obstruction and other causes of dysmotility. Intervention focuses on diet and treatment of the underlying disease. For patients with symptoms despite dietary modifications, prokinetics such as prucalopride or pyridostigmine can be used for symptomatic relief. Pyridostigmine has demonstrated efficacy in the chronic phase of CIPO in small observational studies and is more commonly used in pediatric CIPO.⁷ Through this case, prokinetic agents show promise for broader use in adult CIPO cases.

Conclusion

Adults can be affected by chronic intestinal pseudo-obstruction despite it being a relatively rare disease and being primed to consider it as a diagnosis prevents delays in its treatment and readmissions. Prokinetic agents such as pyridostigmine and prucalopride show promise for broader use in adult CIPO cases.

- PMCID: PMC1774265.
- 2015;152(2):99-105.
- 2018;97(27):e11187.

^{1.} lida H, Ohkubo H, Inamori M, Nakajima A, Sato H. Epidemiology and clinical experience of chronic intestinal pseudoobstruction in Japan: a nationwide epidemiologic survey. J Epidemiol. 2013;23(4):288-94. doi: 10.2188/jea.je20120173. PMID: 23831693; PMCID: PMC3709546.

^{2.} De Giorgio R, Sarnelli G, Corinaldesi R, Stanghellini V. Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction. Gut. 2004 Nov;53(11):1549-52. doi: 10.1136/gut.2004.043968. PMID: 15479666;

^{3.} Stanghellini V, Camilleri M, Malagelada JR. Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings. Gut. 1987 Jan;28(1):5-12. doi: 10.1136/gut.28.1.5. PMID: 3817584; PMCID: PMC1432727. 4. Pereira P, Djeudji F, Leduc P, Fanget F, Barth X. Ogilvie's syndrome-acute colonic pseudo-obstruction. J Visc Surg.

^{5.} Underhill J, Munding E, Hayden D. Acute Colonic Pseudo-obstruction and Volvulus: Pathophysiology, Evaluation, and Treatment. Clin Colon Rectal Surg. 2021;34(4):242-250.

^{6.} Haj M, Haj M, Rockey DC. Ogilvie's syndrome: management and outcomes. Medicine (Baltimore).

^{7.} O'Dea CJ, Brookes JH, Wattchow DA. The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine. Colorectal Dis. 2010 Jun;12(6):540-8. doi: 10.1111/j.1463-1318.2009.01838.x. PMID: 19508545.